Robert Repella is SVP & Chief Commercial Officer at Vanda Pharmaceuticals Inc. (VNDA). They have made 1 open-market trade across 1 company since 2013, most recently 2013-11-21.
CIK 0001532513
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VNDA | 21,490 | $87K |
Shares reported on the most recent Form 4, priced at the 2013-11-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VNDA | SELL | 2013-11-19 | 2013-11-21 | $12.03 | $1.3M | -4.3% | -1.1% | -1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.